<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04430257</url>
  </required_header>
  <id_info>
    <org_study_id>2011002841</org_study_id>
    <secondary_id>R01DA051849-01</secondary_id>
    <nct_id>NCT04430257</nct_id>
  </id_info>
  <brief_title>Pre-exposure Prophylaxis (PrEP) for Health</brief_title>
  <acronym>PrEP</acronym>
  <official_title>Efficacy of a Community-based PrEP Uptake Intervention for People Who Inject Drugs (PWID) in the US Northeast</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brown University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Fenway Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>AIDS Action Committee of Massachusetts</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Greater Lawrence Family Health Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Brown University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized controlled trial will test the efficacy of &quot;PrEP for Health,&quot; a behavioral&#xD;
      intervention to improve the use of antiretroviral pre-exposure prophylaxis (PrEP) among&#xD;
      at-risk people who inject drugs (PWID) in two syringe service program (SSP) settings in&#xD;
      Lawrence and Boston/Cambridge, Massachusetts. The investigators will equally randomize 200&#xD;
      PWID to receive either (a) the &quot;PrEP for Health&quot; intervention condition involving&#xD;
      theory-informed HIV and PrEP education, motivational interviewing, problem-solving and&#xD;
      planning, and ongoing patient navigation (n=100), or (b) the standard of care condition&#xD;
      involving PrEP information and referrals (n=100). Successful PrEP uptake (via&#xD;
      medical/pharmacy records), post-treatment PrEP adherence (assessed at 3 months via drug&#xD;
      levels in hair), and longer-term PrEP adherence (assessed at 6 and 12 months via drug levels&#xD;
      in hair) will be evaluated. The degree to which intervention efficacy occurs through specific&#xD;
      conceptual mediators and differs according to hypothesized moderators will also be evaluated.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The overall goal of this proposal is to evaluate the efficacy of the &quot;PrEP for Health&quot;&#xD;
      navigator delivered behavioral intervention in improving PrEP uptake (via medical/pharmacy&#xD;
      records), post-treatment PrEP adherence (assessed at 3 months via drug levels in hair), and&#xD;
      longer-term PrEP adherence (assessed at 6 and 12 months via drug levels in hair) among PWID&#xD;
      in SSPs. Eligible PWID (n=200 total; 100 recruited from each study site) will be equally&#xD;
      randomized to an active PrEP for Health intervention arm (n=100) or a Standard of Care&#xD;
      control condition (n=100). Assessments will be conducted at baseline and 1, 3, 6, and 12&#xD;
      months after randomization.&#xD;
&#xD;
      We hypothesize that brief, multi-component behavioral intervention sessions with ongoing&#xD;
      support delivered by trained PrEP Navigators within Syringe Service Programs (SSPs) will&#xD;
      improve PrEP uptake, adherence, and long-term adherence in PWID by increasing HIV and PrEP&#xD;
      knowledge (including alleviating concerns about side effects), increasing HIV risk&#xD;
      perceptions and PrEP interest and motivation, improving PrEP use self-efficacy and behavioral&#xD;
      skills, and reducing structural barriers over time. Based on our formative research, we also&#xD;
      hypothesize that the strength of intervention effects may differ by key individual&#xD;
      characteristics (age, gender, baseline sexual risk, polysubstance, and stimulant use).&#xD;
&#xD;
      This is a randomized control trial (RCT). Participants will be recruited via outreach&#xD;
      specialist at SSP sites and during routine community outreach practices of the organizations.&#xD;
      After eligibility confirmation and baseline assessments, participants will be randomized to&#xD;
      one of two study arms: 1) Standard of Care (SOC) Control Condition: as routinely provided&#xD;
      through the SSP study sites, participants will receive information and services according to&#xD;
      routine practice and a brief video that describes what PrEP is and how it works to prevent&#xD;
      HIV via sexual and injection transmission; 2) &quot;PrEP for Health&quot; Intervention Condition: a&#xD;
      trained PrEP Navigator will deliver a manualized PrEP uptake and adherence intervention in&#xD;
      private counseling rooms at SSPs followed by 3 months of additional PrEP navigation support&#xD;
      through in-person, phone, and text interactions as needed. Participants will complete a total&#xD;
      of four follow-up visits over a 12-month period. Participants who initiate PrEP will have a&#xD;
      hair sample collected at 3-, 6-, and 12-month visits. All participants will receive a rapid&#xD;
      HIV screening test at 12-month follow-up.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 2, 2021</start_date>
  <completion_date type="Anticipated">July 2024</completion_date>
  <primary_completion_date type="Anticipated">July 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Individuals collecting the primary outcome data will be blinded to intervention condition.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>PrEP uptake</measure>
    <time_frame>3 months</time_frame>
    <description>PrEP uptake will be assessed via medical/pharmacy records</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Post-treatment PrEP adherence</measure>
    <time_frame>3 months</time_frame>
    <description>PrEP adherence will be assessed by drug levels in hair samples at the acute follow up time point (3 months post-baseline)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Longer-term PrEP adherence</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Longer-term PrEP adherence will be assessed by drug levels in hair samples at 6 and 12-month post-baseline</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Substance Dependence</condition>
  <condition>HIV (Human Immunodeficiency Virus)</condition>
  <arm_group>
    <arm_group_label>PrEP for health</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in the PrEP (pre-exposure prophylaxis) for health arm will receive theory informed HIV and PrEP education, motivational interviewing, problem-solving and planning, and ongoing patient navigation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants in the standard of care arm will receive PrEP information and referrals.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>HIV and PrEP education</intervention_name>
    <description>Navigators will deliver Social Cognitive Theory-informed HIV and PrEP education.</description>
    <arm_group_label>PrEP for health</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Motivational interviewing</intervention_name>
    <description>Bachelors-level PrEP Navigators who are trained in motivational interviewing (MI) will use MI to promote the behavioral intervention.</description>
    <arm_group_label>PrEP for health</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Problem-solving and planning</intervention_name>
    <description>Bachelors-level PrEP Navigators will assist participants with problem-solving and planning.</description>
    <arm_group_label>PrEP for health</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Patient navigation</intervention_name>
    <description>Ongoing PrEP navigation support to promote participants' initial and continued engagement with PrEP clinics affiliated with the two study sites</description>
    <arm_group_label>PrEP for health</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>PrEP information</intervention_name>
    <description>A brief video that describes what PrEP is and how it works to prevent HIV via sexual and injection transmission will be shown to participants.</description>
    <arm_group_label>PrEP for health</arm_group_label>
    <arm_group_label>Standard of care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Referrals</intervention_name>
    <description>Study staff will provide basic information about PrEP and referrals to PrEP clinicians.</description>
    <arm_group_label>Standard of care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  HIV-uninfected (verified by rapid/4th generation test)&#xD;
&#xD;
          -  Reporting past-month injection of any drugs&#xD;
&#xD;
          -  One or more HIV risk behaviors (past-month receptive syringe sharing, transactional&#xD;
             sex, or condomless sex with an HIV-infected or unknown-status partner)&#xD;
&#xD;
          -  Not currently on and never taken PrEP&#xD;
&#xD;
          -  Able to understand and speak English or Spanish&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unable to provide informed consent due to severe mental or physical illness, cognitive&#xD;
             impairment, or substance intoxication at the time of enrollment&#xD;
&#xD;
          -  Living in Massachusetts (MA) for &lt;3 months&#xD;
&#xD;
          -  Planning to move out of MA within a year&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katie Biello, PhD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brown University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Angela Bazzi, PhD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Diego</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Katie Biello, PhD, MPH</last_name>
    <phone>401-863-6551</phone>
    <email>katie_biello@brown.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jennifer Olson, MBA</last_name>
    <phone>401-863-3292</phone>
    <email>jennifer_olson1@brown.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>AIDS Action</name>
      <address>
        <city>Cambridge</city>
        <state>Massachusetts</state>
        <zip>02139</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cassidy Ockene</last_name>
      <phone>617-927-6286</phone>
      <email>cockene@fenwayhealth.org</email>
    </contact>
    <investigator>
      <last_name>Michelle Bordeu, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Greater Lawrence Family Health Center</name>
      <address>
        <city>Lawrence</city>
        <state>Massachusetts</state>
        <zip>01841</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Bositis, MD</last_name>
      <phone>978-689-6444</phone>
      <email>cbositis@glfhc.org</email>
    </contact>
    <investigator>
      <last_name>Christopher Bositis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Katrina Baumgartner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 10, 2020</study_first_submitted>
  <study_first_submitted_qc>June 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 12, 2020</study_first_posted>
  <last_update_submitted>September 22, 2021</last_update_submitted>
  <last_update_submitted_qc>September 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PrEP (pre-exposure prophylaxis )</keyword>
  <keyword>PWID (people who inject drugs)</keyword>
  <keyword>SSP (syringe service program)</keyword>
  <keyword>HIV education</keyword>
  <keyword>Motivational interviewing</keyword>
  <keyword>Self efficacy</keyword>
  <keyword>Social cognitive theory</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Substance-Related Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>By request to the study investigators</ipd_description>
    <ipd_time_frame>Data will be available after the study has closed and after publication of the primary study findings.</ipd_time_frame>
    <ipd_access_criteria>Requests will be reviewed by the principal investigators.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

